- Home
- BLUE vs IMRX Comparison
BLUE vs IMRX Comparison
Compare BLUE & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLUE
- IMRX
- Stock Information
- Founded
- BLUE 1992
- IMRX 2008
- Country
- BLUE United States
- IMRX United States
- Employees
- BLUE N/A
- IMRX N/A
- Industry
- BLUE Biotechnology: Biological Products (No Diagnostic Substances)
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- BLUE Health Care
- IMRX Health Care
- Exchange
- BLUE Nasdaq
- IMRX Nasdaq
- Market Cap
- BLUE 62.1M
- IMRX 62.7M
- IPO Year
- BLUE 2013
- IMRX 2021
- Fundamental
- Price
- BLUE $4.08
- IMRX $1.76
- Analyst Decision
- BLUE Hold
- IMRX Buy
- Analyst Count
- BLUE 9
- IMRX 7
- Target Price
- BLUE $49.14
- IMRX $12.20
- AVG Volume (30 Days)
- BLUE 458.1K
- IMRX 319.9K
- Earning Date
- BLUE 03-25-2025
- IMRX 03-04-2025
- Dividend Yield
- BLUE N/A
- IMRX N/A
- EPS Growth
- BLUE N/A
- IMRX N/A
- EPS
- BLUE N/A
- IMRX N/A
- Revenue
- BLUE $53,120,000.00
- IMRX N/A
- Revenue This Year
- BLUE $145.30
- IMRX N/A
- Revenue Next Year
- BLUE $240.19
- IMRX N/A
- P/E Ratio
- BLUE N/A
- IMRX N/A
- Revenue Growth
- BLUE 144.50
- IMRX N/A
- 52 Week Low
- BLUE $4.00
- IMRX $1.00
- 52 Week High
- BLUE $38.40
- IMRX $7.68
- Technical
- Relative Strength Index (RSI)
- BLUE 26.22
- IMRX 40.02
- Support Level
- BLUE $6.61
- IMRX $1.70
- Resistance Level
- BLUE $7.55
- IMRX $1.92
- Average True Range (ATR)
- BLUE 0.64
- IMRX 0.09
- MACD
- BLUE -0.11
- IMRX -0.01
- Stochastic Oscillator
- BLUE 2.24
- IMRX 15.00
About BLUE bluebird bio Inc.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.